Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Plasmacytoma trials

The registry lists 15 Plasmacytoma studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 0 are open to participants now and 7 have results posted.

Early Phase 1 1Phase 1 6Phase 2 8Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Activated White Blood Cells With ASCT for Newly Diagnosed Multiple MyelomaCompletedNCT00566098Phase 1/2Results posted
• Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple MyelomaTerminatedNCT00470093Early Phase 1Results posted
• Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00445484Phase 2Results posted
• Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple MyelomaCompletedNCT00258206Phase 2Results posted
• Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerCompletedNCT00134017Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00134004Phase 2Results posted
• Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell TransplantTerminatedNCT00469820Phase 1
• Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
• Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic CancerCompletedNCT00255710Phase 1
• MS-275 in Treating Patients With Hematologic CancerCompletedNCT00015925Phase 1
• Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00006042Phase 1
• Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003962Phase 1
• Donor Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003960Phase 2
• Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancersCompletedNCT00003572Phase 2